Influence of atorvastatin on osteopontin expression following kidney transplantation in rats

Liu Min,Wu Yi-chao,Zhang Wei,g M,Zhang Wei

2007-01-01

Abstract:AIM: To investigate the effect of atorvastatin on the renal expression of osteopontin in rats' kidney allograft model. METHODS: The experiment was conducted in the Laboratory of Pathology of Nanjing Medical University between August and December 2005. Totally 35 inbred male SD rats were used as recipients and 35 male Wistar rats as donors, which weighed 250-300 g. Firstly synergistic kidney allograft model was established, thereafter the recipients were randomized into three groups, 10 rats in each group: ciclosporin A group, ciclosporin A plus low-dosage atorvastatin group and ciclosporin A plus high-dosage atorvastatin group. ①Blood was isolated at day 7 and week 4 after operation to measure serum creatinine. Animals were killed at week 4 after operation to take out kidney. BANFF score was compared under light microscope. ②Osteopontin expression of nephridial tissue was examined with immunohistochemical method, and the percentage of positive tubule of osteopontin was compared with image analysis software. ③Osteopontin mRNA expression was identified with blotting and in situ hybridization. ④Numeration data and measurement data were examined with χ2 test and t test. Inter-group difference was compared with Mann-Whitney U test. RESULTS: Totally 60 kidney transplantation in rats were performed, of which there were 25 preliminary experiments with 10 dead recipients and 35 formal experiments with 5 dead recipients. The other rats lived over 30 days with the survival rate of 85.7% (30/35). The 30 survival rats were assigned into 3 observational groups. ①The renal function of rats in the ciclosporin A plus low-dosage atorvastatin group and ciclosporin A plus high-dosage atorvastatin group was obviously better than that in the ciclosporin A group (P < 0.05). ②The structure of renal corpuscle was near to normal in each group under light microscope, but the infiltration of inflammatory cells in matrix and inflammatory level of tubule in the ciclosporin A plus low-dosage atorvastatin group and ciclosporin A plus high-dosage atorvastatin group were mild as compared with the ciclosporin A group. ③Immunohistochemical method showed that only little osteopontin appeared in Henle of normal nephridial tissues. Four weeks after ciclosporin A treatment, the osteopontin expression was markedly prominent in cortical collecting duct, while the osteopontin expression was remarkably mild in the ciclosporin A plus low-dosage atorvastatin group and ciclosporin A plus high-dosage atorvastatin group. The effect of atorvastatin in reduction of osteopontin expression had dose dependent. ④The osteopontin mRNA expression in grafting kidney was distinctly lower than that in the ciclosporin A group identified with blotting and in situ hybridization (P < 0.01), and had positive correlation with atorvastatin dosage. CONCLUSION: Atorvastatin can significantly inhibit the expression of osteopontin in allografts. Atorvastatin is helpful for relieving inflammation and renal vascular disease, reduce ciclosporin nephrotoxicity and delay chronic allograft nephropathy (CAN) in patients with kidney transplantation.